OVID

Ovid Therapeutics Inc. is a biopharmaceutical company based in New York that develops small molecule medicines for neurological and brain conditions, particularly focusing on epilepsy and related disorders. The company is advancing a pipeline of targeted candidates, including OV329, a GABA-aminotransferase inhibitor for treatment-resistant seizures, and OV4071, which activates the KCC2 transporter for various central nervous system disorders. Ovid aims to address the needs of patients who experience seizures despite current treatments and seeks to improve their quality of life.